Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 6Other solid neoplasm 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1

Interventions

Oxaliplatin 197Bevacizumab 161Fluorouracil 154Capecitabine 137Gemcitabine 134Leucovorin 111pembrolizumab 99Cisplatin 94Drug Therapy 89Irinotecan 80Radiotherapy 73sintilimab 70130-nm albumin-bound paclitaxel 66durvalumab 65Paclitaxel 64Specimen Handling 62Cetuximab 61lenvatinib 59tislelizumab 58Nivolumab 55Magnetic Resonance Spectroscopy 55Folfox protocol 55Blood Specimen Collection 52atezolizumab 47Biopsy 46Surgical Procedures, Operative 40Taxes 39Albumin-Bound Paclitaxel 39Immune Checkpoint Inhibitors 37HMPL-013 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × 1-dodecylpyridoxal × Gastrointestinal × Clear all
NCT05536102 2023-03-09

The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡